Abstract
Aim: To examine the effectiveness of eribulin mesylate for metastatic breast cancer post cyclin-dependent kinase inhibitor (CDKi) 4/6 therapy. Materials & methods: US community oncologists reviewed charts of patients who had received eribulin from 3 February 2015 to 31 December 2017 after prior CDKi 4/6 therapy and detailed their clinical/treatment history, clinical outcomes (lesion measurements, progression, death) and toxicity. Results: Four patient cohorts were created according to eribulin line of therapy: second line, third line, per US label and fourth line with objective response rates/clinical benefit rates of 42.2%/58.7%, 26.1%/42.3%, 26.7%/54.1% and 17.9%/46.4%, respectively. Median progression-free survival/6-month progression-free survival (79.5% of all patients censored) by cohort was: 9.7 months/77.3%, 10.3 months/71.3%, not reached/70.4% and 4.0 months/0.0%, respectively. Overall occurrence of neutropenia = 23.5%, febrile neutropenia = 1.3%, peripheral neuropathy = 10.1% and diarrhea = 11.1%. Conclusion: Clinical outcome and adverse event rates were similar to those in clinical trials and other observational studies. Longer follow-up is required to confirm these findings.
Keywords:
breast; chemotherapy; hormonal therapy; outcomes research; palliative/end-of-life care; real-world evidence.
MeSH terms
-
Adult
-
Aged
-
Aminopyridines / administration & dosage
-
Aminopyridines / adverse effects
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Benzimidazoles / administration & dosage
-
Benzimidazoles / adverse effects
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology
-
Breast Neoplasms / therapy*
-
Chemotherapy, Adjuvant / methods
-
Chemotherapy-Induced Febrile Neutropenia / epidemiology
-
Chemotherapy-Induced Febrile Neutropenia / etiology
-
Cyclin-Dependent Kinase 4 / antagonists & inhibitors
-
Cyclin-Dependent Kinase 6 / antagonists & inhibitors
-
Diarrhea / chemically induced
-
Diarrhea / epidemiology
-
Disease Progression
-
Female
-
Follow-Up Studies
-
Furans / administration & dosage*
-
Furans / adverse effects
-
Humans
-
Ketones / administration & dosage*
-
Ketones / adverse effects
-
Mastectomy
-
Middle Aged
-
Neoadjuvant Therapy / methods
-
Palliative Care / methods*
-
Palliative Care / trends
-
Peripheral Nervous System Diseases / chemically induced
-
Peripheral Nervous System Diseases / epidemiology
-
Piperazines / administration & dosage
-
Piperazines / adverse effects
-
Progression-Free Survival
-
Protein Kinase Inhibitors / administration & dosage*
-
Protein Kinase Inhibitors / adverse effects
-
Purines / administration & dosage
-
Purines / adverse effects
-
Pyridines / administration & dosage
-
Pyridines / adverse effects
-
Treatment Outcome
-
United States / epidemiology
-
Young Adult
Substances
-
Aminopyridines
-
Antineoplastic Agents
-
Benzimidazoles
-
Furans
-
Ketones
-
Piperazines
-
Protein Kinase Inhibitors
-
Purines
-
Pyridines
-
abemaciclib
-
CDK4 protein, human
-
CDK6 protein, human
-
Cyclin-Dependent Kinase 4
-
Cyclin-Dependent Kinase 6
-
palbociclib
-
eribulin
-
ribociclib